Cargando…
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567818/ http://dx.doi.org/10.1192/j.eurpsy.2022.1857 |
_version_ | 1784809494744662016 |
---|---|
author | Costa, M.L. Cerame, A. |
author_facet | Costa, M.L. Cerame, A. |
author_sort | Costa, M.L. |
collection | PubMed |
description | INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased her levodopa intake by three times the recommended dose. The patient presented many adverse effects, including psychotic symptoms, that were interrupted after the levodopa intake was ended during a two month internament in a psychiatric unit. Dopamine dysregulation syndrome (DDS) is a condition in which patients with PD increase their levodopa intake without an objective worsening of motor symptoms. Higher-than-prescribed doses are taken by patients who develop tolerance and dependence to dopaminergic agonists. OBJECTIVES: To analyse the prevalence of DDS, its diagnosis and treatment as well as the identification of risk factors. METHODS: A case report is presented alongside a review of the relevant literature regarding DDS. RESULTS: The available evidence suggests that the main risk factors for DDS are a history of mood disorders and behavioural disorders, but more studies are needed. Given that DDS is considered a rare adverse effect, physicians usually overlook voluntary dose increase by patients. CONCLUSIONS: DDS, even though uncommon, has severe adverse effects such as dependence and acute psychosis. Before prescription of dopamine agonists, individual risk factors (such as psychiatric comorbidities or history of substance abuse) should be assessed. Also, patients and families should be informed and trained in alarm signs detection. Further studies would be justified to determine DDS prevalence, early diagnosis and treatment. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9567818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95678182022-10-17 Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report Costa, M.L. Cerame, A. Eur Psychiatry Abstract INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased her levodopa intake by three times the recommended dose. The patient presented many adverse effects, including psychotic symptoms, that were interrupted after the levodopa intake was ended during a two month internament in a psychiatric unit. Dopamine dysregulation syndrome (DDS) is a condition in which patients with PD increase their levodopa intake without an objective worsening of motor symptoms. Higher-than-prescribed doses are taken by patients who develop tolerance and dependence to dopaminergic agonists. OBJECTIVES: To analyse the prevalence of DDS, its diagnosis and treatment as well as the identification of risk factors. METHODS: A case report is presented alongside a review of the relevant literature regarding DDS. RESULTS: The available evidence suggests that the main risk factors for DDS are a history of mood disorders and behavioural disorders, but more studies are needed. Given that DDS is considered a rare adverse effect, physicians usually overlook voluntary dose increase by patients. CONCLUSIONS: DDS, even though uncommon, has severe adverse effects such as dependence and acute psychosis. Before prescription of dopamine agonists, individual risk factors (such as psychiatric comorbidities or history of substance abuse) should be assessed. Also, patients and families should be informed and trained in alarm signs detection. Further studies would be justified to determine DDS prevalence, early diagnosis and treatment. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567818/ http://dx.doi.org/10.1192/j.eurpsy.2022.1857 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Costa, M.L. Cerame, A. Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title | Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title_full | Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title_fullStr | Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title_full_unstemmed | Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title_short | Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
title_sort | dopamine dysregulation syndrome after prescription of dopamine agonists: a case report |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567818/ http://dx.doi.org/10.1192/j.eurpsy.2022.1857 |
work_keys_str_mv | AT costaml dopaminedysregulationsyndromeafterprescriptionofdopamineagonistsacasereport AT ceramea dopaminedysregulationsyndromeafterprescriptionofdopamineagonistsacasereport |